Properties of Stereodefined Variants of Nusinersen

In the pharmaceutical industry, stereopure drugs are generally preferred over isomeric mixtures to reduce the risks of side effects and to simplify pharmacodynamics (PD) and pharmacokinetics (PK) properties. This reasoning applies equally to antisense oligonucleotides (ASOs). All current ASO drugs are modified to provide appropriate PK/PD properties. Among the modifications, phosphorothioate (PS) groups provide essential nuclease resistance and advantageous biodistribution properties. However, PS groups are chiral, with R p- and S p-centers that are challenging to incorporate stereoselectively during solid-phase synthesis, and thus current ASO drugs are diastereoisomeric mixtures. Here, we describe the synthesis of stereodefined variants of the approved drug nusinersen (Spinraza), a 2′- O -methoxyethyl-modified oligonucleotide that redirects splicing of SMN2 during treatment for spinal muscular atrophy (SMA). We found that a single 3′- S p linkage stabilizes nusinersen from degradation in mouse tissue homogenates. Although R p-nusinersen has higher target-binding affinity than S p-nusinersen, it is not more active than parent nusinersen in patient-derived cells. Finally, we show mixed results from comparing stereodefined nusinersen with parent nusinersen in a murine model of SMA. While our data do not provide definitive evidence for the superior performance of stereodefined nusinersen, we conclude that it is likely equally effective as its parent ASO, while bearing the pharmacological advantages of a single stereoisomer.

Authors

Institutions

Publication Details

Journal
Nucleic Acid Therapeutics
Published
2026-11-13
DOI
https://doi.org/10.1177/21593337261502915
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Properties of Stereodefined Variants of Nusinersen

Krainer Adrian r., Jonathan Hall, Anastasia Lepikhina, Eva-Maria Manz et al.
2 links
Nucleic Acid Therapeutics
RNA Interference and Gene Delivery
article

Properties of Stereodefined Variants of Nusinersen

Krainer Adrian r., Jonathan Hall, Anastasia Lepikhina, Eva-Maria Manz, Ying Hsiu Liu, Erick E Nakagaki-Silva, Lucia Yang, Angel Santorelli, Mathilde Vincent
article en

Abstract

In the pharmaceutical industry, stereopure drugs are generally preferred over isomeric mixtures to reduce the risks of side effects and to simplify pharmacodynamics (PD) and pharmacokinetics (PK) properties. This reasoning applies equally to antisense oligonucleotides (ASOs). All current ASO drugs are modified to provide appropriate PK/PD properties. Among the modifications, phosphorothioate (PS) groups provide essential nuclease resistance and advantageous biodistribution properties. However, PS groups are chiral, with R p- and S p-centers that are challenging to incorporate stereoselectively during solid-phase synthesis, and thus current ASO drugs are diastereoisomeric mixtures. Here, we describe the synthesis of stereodefined variants of the approved drug nusinersen (Spinraza), a 2′- O -methoxyethyl-modified oligonucleotide that redirects splicing of SMN2 during treatment for spinal muscular atrophy (SMA). We found that a single 3′- S p linkage stabilizes nusinersen from degradation in mouse tissue homogenates. Although R p-nusinersen has higher target-binding affinity than S p-nusinersen, it is not more active than parent nusinersen in patient-derived cells. Finally, we show mixed results from comparing stereodefined nusinersen with parent nusinersen in a murine model of SMA. While our data do not provide definitive evidence for the superior performance of stereodefined nusinersen, we conclude that it is likely equally effective as its parent ASO, while bearing the pharmacological advantages of a single stereoisomer.

Nucleic Acid Therapeutics
Cold Spring Harbor Laboratory (US), ETH Zurich (CH), Institute of Pharmaceutical Sciences (CH)
St. Giles Foundation
Good health and well-being
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon